This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01189175
First received: August 25, 2010
Last updated: October 31, 2013
Last verified: October 2013
August 25, 2010
October 31, 2013
August 2010
September 2010   (Final data collection date for primary outcome measure)
  • AUC0-∞(area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) of BI 113823 [ Time Frame: 2 weeks ]
  • Cmax (maximum measured concentration of the analyte in plasma) of BI 113823 [ Time Frame: 2 weeks ]
Relative bioavailability is primarily to be investigated on the basis of the pharmacokinetic parameters (AUC and Cmax) of BI 113823: [ Time Frame: 2 weeks ]
Complete list of historical versions of study NCT01189175 on ClinicalTrials.gov Archive Site
  • AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) [ Time Frame: 2 weeks ]
  • Number of participants with clinically significant changes in physical examination [ Time Frame: up to 24 days ]
  • Number of participants with clinically significant changes in vital signs [ Time Frame: up to 24 days ]
  • Number of participants with clinically significant changes in ECG [ Time Frame: up to 24 days ]
  • Number of participants with clinically significant changes in laboratory tests [ Time Frame: up to 24 days ]
  • Occurrence of adverse events [ Time Frame: up to 24 days ]
  • Assessment of tolerability by the investigator [ Time Frame: up to 24 days ]
  • AUCt1-t2 (Area under the concentration time curve of the analyte in plasma over the time interval t1 to t2) [ Time Frame: 2 weeks ]
  • AUC0-tmax (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to median tmax [ Time Frame: 2 weeks ]
  • tmax (time from dosing to the maximum concentration of the analyte in plasma) [ Time Frame: 2 weeks ]
  • λz (terminal rate constant in plasma) t1/2 (terminal half-life of the analyte in plasma [ Time Frame: 2 weeks ]
  • t1/2 (terminal half-life of the analyte in plasma) [ Time Frame: 2 weeks ]
  • MRTpo (mean residence time of the analyte in the body after po administration) [ Time Frame: 2 weeks ]
  • CL/F (apparent clearance of the analyte in the plasma after extravascular administration) [ Time Frame: 2 weeks ]
  • Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) [ Time Frame: 2 weeks ]
  • Ae0-24 (amount of analyte that is eliminated in urine from the time interval 0 to 24) [ Time Frame: visit 2, day 1 and visit 4 day 1 ]
  • fe0-24 (fraction of administered drug excreted unchanged in urine from time point 0 to 24 [ Time Frame: visit 2, day 1 and visit 4 day 1 ]
  • CLR,0-24 (renal clearance of the analyte in plasma from the time point 0 until the time point 24) [ Time Frame: visit 2, day 1 and visit 4 day 1 ]
  • Additional pharmacokinetic parameters will be assessed for BI 113823 as secondary endpoints [ Time Frame: 2 weeks ]
  • Safety and tolerability (physical examination, ECG, vital signs...) [ Time Frame: 2 Weeks ]
Not Provided
Not Provided
 
Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823
Relative Bioavailability of a Single Oral Dose of BI 113823 (50 mg qd) When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole (200 mg Bid) in Healthy Male Volunteers (an Open Label, Two Periods, Fixed-sequence, Clinical Phase I Study)
The objective of the study is to investigate whether ketoconazole affects plasma exposure of BI 113823
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy
  • Drug: BI 113823 + Ketokonazole
    5 days ketokonazole with single oral dose of BI 113823 on day 3
  • Drug: BI 113823
    single oral dose
  • Experimental: BI 113823
    single oral dose per subject
    Intervention: Drug: BI 113823
  • Experimental: BI 113823 + Ketokonazole
    after wash-out 5 days ketokonazole with BI 113823 on day 3
    Intervention: Drug: BI 113823 + Ketokonazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
Not Provided
September 2010   (Final data collection date for primary outcome measure)

Inclusion criteria:

healthy male subjects

Sexes Eligible for Study: Male
18 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01189175
1272.5
2010-018542-31 ( EudraCT Number: EudraCT )
Not Provided
Not Provided
Not Provided
Not Provided
Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP